These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

252 related items for PubMed ID: 12429628

  • 1. Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer.
    Murray JL, Gillogly ME, Przepiorka D, Brewer H, Ibrahim NK, Booser DJ, Hortobagyi GN, Kudelka AP, Grabstein KH, Cheever MA, Ioannides CG.
    Clin Cancer Res; 2002 Nov; 8(11):3407-18. PubMed ID: 12429628
    [Abstract] [Full Text] [Related]

  • 2. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes.
    Brossart P, Stuhler G, Flad T, Stevanovic S, Rammensee HG, Kanz L, Brugger W.
    Cancer Res; 1998 Feb 15; 58(4):732-6. PubMed ID: 9485028
    [Abstract] [Full Text] [Related]

  • 3. Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients.
    Peoples GE, Gurney JM, Hueman MT, Woll MM, Ryan GB, Storrer CE, Fisher C, Shriver CD, Ioannides CG, Ponniah S.
    J Clin Oncol; 2005 Oct 20; 23(30):7536-45. PubMed ID: 16157940
    [Abstract] [Full Text] [Related]

  • 4. Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity.
    Knutson KL, Schiffman K, Cheever MA, Disis ML.
    Clin Cancer Res; 2002 May 20; 8(5):1014-8. PubMed ID: 12006513
    [Abstract] [Full Text] [Related]

  • 5. Levels of circulating regulatory CD4+CD25+ T cells are decreased in breast cancer patients after vaccination with a HER2/neu peptide (E75) and GM-CSF vaccine.
    Hueman MT, Stojadinovic A, Storrer CE, Foley RJ, Gurney JM, Shriver CD, Ponniah S, Peoples GE.
    Breast Cancer Res Treat; 2006 Jul 20; 98(1):17-29. PubMed ID: 16758122
    [Abstract] [Full Text] [Related]

  • 6. Clinical and immunologic responses of HLA-A3+ breast cancer patients vaccinated with the HER2/neu-derived peptide vaccine, E75, in a phase I/II clinical trial.
    Patil R, Clifton GT, Holmes JP, Amin A, Carmichael MG, Gates JD, Benavides LH, Hueman MT, Ponniah S, Peoples GE.
    J Am Coll Surg; 2010 Feb 20; 210(2):140-7. PubMed ID: 20113933
    [Abstract] [Full Text] [Related]

  • 7. Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
    Holmes JP, Gates JD, Benavides LC, Hueman MT, Carmichael MG, Patil R, Craig D, Mittendorf EA, Stojadinovic A, Ponniah S, Peoples GE.
    Cancer; 2008 Oct 01; 113(7):1666-75. PubMed ID: 18726994
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial.
    Mittendorf EA, Storrer CE, Foley RJ, Harris K, Jama Y, Shriver CD, Ponniah S, Peoples GE.
    Cancer; 2006 Jun 01; 106(11):2309-17. PubMed ID: 16596621
    [Abstract] [Full Text] [Related]

  • 9. Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer.
    Kono K, Takahashi A, Sugai H, Fujii H, Choudhury AR, Kiessling R, Matsumoto Y.
    Clin Cancer Res; 2002 Nov 01; 8(11):3394-400. PubMed ID: 12429626
    [Abstract] [Full Text] [Related]

  • 10. Phase I clinical trial of a HER-2/neu peptide (E75) vaccine for the prevention of prostate-specific antigen recurrence in high-risk prostate cancer patients.
    Hueman MT, Dehqanzada ZA, Novak TE, Gurney JM, Woll MM, Ryan GB, Storrer CE, Fisher C, McLeod DG, Ioannides CG, Ponniah S, Peoples GE.
    Clin Cancer Res; 2005 Oct 15; 11(20):7470-9. PubMed ID: 16243821
    [Abstract] [Full Text] [Related]

  • 11. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine.
    Disis ML, Grabstein KH, Sleath PR, Cheever MA.
    Clin Cancer Res; 1999 Jun 15; 5(6):1289-97. PubMed ID: 10389911
    [Abstract] [Full Text] [Related]

  • 12. Stimulation of cells from a non-invaded and an invaded lymph node with a HER-2+ tumor with peptides corresponding to T-cell epitopes E75 and G89 induced expansion of central memory cells (TCM) from the metastasis-negative lymph nodes.
    Ko BK, Efferson CL, Kawano K, Kuerer HM, Sahin A, Murray JL, Ioannides CG.
    Int J Oncol; 2004 Jun 15; 24(6):1413-8. PubMed ID: 15138582
    [Abstract] [Full Text] [Related]

  • 13. Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
    Peoples GE, Holmes JP, Hueman MT, Mittendorf EA, Amin A, Khoo S, Dehqanzada ZA, Gurney JM, Woll MM, Ryan GB, Storrer CE, Craig D, Ioannides CG, Ponniah S.
    Clin Cancer Res; 2008 Feb 01; 14(3):797-803. PubMed ID: 18245541
    [Abstract] [Full Text] [Related]

  • 14. Peptide priming of cytolytic activity to HER-2 epitope 369-377 in healthy individuals.
    Anderson BW, Peoples GE, Murray JL, Gillogly MA, Gershenson DM, Ioannides CG.
    Clin Cancer Res; 2000 Nov 01; 6(11):4192-200. PubMed ID: 11106231
    [Abstract] [Full Text] [Related]

  • 15. Diverse CD8+ T-cell responses to renal cell carcinoma antigens in patients treated with an autologous granulocyte-macrophage colony-stimulating factor gene-transduced renal tumor cell vaccine.
    Zhou X, Jun DY, Thomas AM, Huang X, Huang LQ, Mautner J, Mo W, Robbins PF, Pardoll DM, Jaffee EM.
    Cancer Res; 2005 Feb 01; 65(3):1079-88. PubMed ID: 15705910
    [Abstract] [Full Text] [Related]

  • 16. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma.
    von Mehren M, Arlen P, Gulley J, Rogatko A, Cooper HS, Meropol NJ, Alpaugh RK, Davey M, McLaughlin S, Beard MT, Tsang KY, Schlom J, Weiner LM.
    Clin Cancer Res; 2001 May 01; 7(5):1181-91. PubMed ID: 11350882
    [Abstract] [Full Text] [Related]

  • 17. Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides.
    Salgaller ML, Afshar A, Marincola FM, Rivoltini L, Kawakami Y, Rosenberg SA.
    Cancer Res; 1995 Nov 01; 55(21):4972-9. PubMed ID: 7585538
    [Abstract] [Full Text] [Related]

  • 18. Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors.
    Zaks TZ, Rosenberg SA.
    Cancer Res; 1998 Nov 01; 58(21):4902-8. PubMed ID: 9809997
    [Abstract] [Full Text] [Related]

  • 19. Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer.
    Linehan DC, Goedegebuure PS, Peoples GE, Rogers SO, Eberlein TJ.
    J Immunol; 1995 Nov 01; 155(9):4486-91. PubMed ID: 7594611
    [Abstract] [Full Text] [Related]

  • 20. Correlations between serum monocyte chemotactic protein-1 levels, clinical prognostic factors, and HER-2/neu vaccine-related immunity in breast cancer patients.
    Dehqanzada ZA, Storrer CE, Hueman MT, Foley RJ, Harris KA, Jama YH, Kao TC, Shriver CD, Ponniah S, Peoples GE.
    Clin Cancer Res; 2006 Jan 15; 12(2):478-86. PubMed ID: 16428490
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.